Abstract: Background: PPH is the most frequent cause of maternal mortality, accounting for over 35% of maternal deaths globally. Tranexamic acid is advised to be administered in all PPH patients, regardless of the etiology of PPH, and should be regarded as a standard complete PPH therapy package.
Objective: To assess the efficiency and safety of intravenous tranexamic acid (TA) for reducing postpartum blood loss after vaginal birth and LSCS, as well as to keep track of any negative effects that may occur.
Materials and Methods: Females at high risk of PPH who were delivered vaginally or through LSCS were included in this research, which was done as a randomized, double-blind, placebo-controlled experiment at our Institute. All individuals were divided into the study group (tranexamic acid) and control group at random. The effectiveness (volume of blood loss and incidence of PPH) and safety (vitals and side effects) of the two groups were compared.
Results: In comparison to the control group, the study group's mean blood loss was considerably lower from the time the placenta was delivered until the conclusion of labor and from that point until two hours after delivery (p 0.05). In the control group, PPH incidence was substantially greater (p 0.05). Between the two groups, there was no statistically significant difference in the vital signs (p>0.05). The study group's most prevalent tranexamic acid adverse effect was nausea (16%), which was followed by vomiting and diarrhea (9% and 1%, respectively).
Conclusion: Regardless of the origin of PPH, tranexamic acid is a powerful medication that may be administered safely for preventive therapy. Regardless of the method of administration, this antifibrinolytic drug dramatically reduces blood loss and PPH incidence. Although the medicine is linked to mild adverse effects including nausea, vomiting, and diarrhea, significant consequences like thromboembolic phenomena, maternal or neonatal morbidity, and death have not been reported.
Indexed in Index Copernicus
